XTalks

JANUARY 2, 2024

For instance, Vyjuvek , the first FDA-approved gene therapy for DEB, is priced at $24,250 per vial. Vyjuvek is a gene therapy that employs a herpes simplex virus type 1 (HSV-1) vector. EB-101, an engineered cell therapy for RDEB, demonstrated a substantial improvement in wound healing (81.4 percent) at the six-month mark.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

The Pharma Data

DECEMBER 10, 2020

He became Head of Development for Rare Diseases and Gene Therapy in Sanofi-Genzyme’s office in Cambridge, Massachusetts. Dr Pirozzi subsequently was inspired to pursue a career in rare diseases after his daughter Valentina was diagnosed with a rare chromosomal syndrome, called Smith-Magenis Syndrome. positions he assumed in 2020.

Research 52

Research Doctor Doctors Medicine 52

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to Aktana, Daveynis served as vice president of engineering at Verint and held prior leadership roles at Capsilon, Quantros, HP, and Kodak.

Development 52

Development Gene Therapy Engineer Life Science 52

Scienmag

OCTOBER 19, 2020

Garrido, CNIO The sophisticated human immune system has evolved to become an effective protection system against a great number of diseases, cancer being one of them. The immune system recognises and destroys cancer cells using a monitoring process called immunological surveillance.

Dermatology 52

Dermatology Allergies Gene Genetics 52

The Pharma Data

SEPTEMBER 15, 2020

With the depth and breadth of our current portfolio, the tremendous potential of our pipeline and scientific engine, and the power of our culture of innovation, we are poised to continue delivering meaningful value to patients by addressing some of the world’s most difficult health challenges.”. Inflammation and Immunology.

Vaccination 52

Vaccination Vaccine Gene Therapy Trials 52

The Pharma Data

JANUARY 24, 2021

CYAD-101 is the company’s allogeneic NKG2D-receptor and T cell receptor inhibitory molecule-based, non-gene edited CAR-T candidate. oncolytic virus (VVcopTK-RR-) and engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody and the human GM-CSF cytokine. It is being administered together with FOLFOX chemotherapy.

Trials 52

Trials Allergies In-Vitro Antibody 52